StageAsset Sale | AssetsPurchased
uBiome is a citizen science startup that sequences the human microbiome and allows the public access to sequencing technology. uBiome's commercial products include SmartGut, a sequencing-based clinical microbiome test, which identifies microbes in the gut for patients with chronic gut conditions such as IBD, IBS, Crohn's Disease, and ulcerative colitis; SmartJane, a sequencing-based women's health screening test, which genotypes all 19 clinically relevant strains of HPV, identifies four common STDs, and surveys more than 20 vaginal microbes associated with bacterial vaginosis and other conditions; and Explorer, a health and wellness product to understand the role that food and lifestyle can play in wellness. In January 2020, a consortium by Psomagen-Macrogen acquired all the asset of uBiome.
Missing: uBiome's Product Demo & Case Studies
Promote your product offering to tech buyers.
Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.
Missing: uBiome's Product & Differentiators
Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).
Research containing uBiome
Get data-driven expert analysis from the CB Insights Intelligence Unit.
CB Insights Intelligence Analysts have mentioned uBiome in 2 CB Insights research briefs, most recently on Apr 24, 2023.
Apr 18, 2023452 startup failure post-mortems
Expert Collections containing uBiome
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
uBiome is included in 6 Expert Collections, including Women's Health & Wellness.
Women's Health & Wellness
Startups focused on providing products and services catering to women's health and wellbeing.
Companies developing medical devices (per the IMDRF's definition of "medical device"). Includes software, lab-developed tests (LDTs), and combination products. *Columns updated as regularly as possible.
Health Monitoring & Diagnostics
Companies developing or offering products that aid in the assessment, screening, diagnosis, or monitoring of a person's state of health/wellness. Excludes companies focused solely on fitness/sports performance
The digital health collection includes vendors developing software, platforms, sensor & robotic hardware, health data infrastructure, and tech-enabled services in healthcare. The list excludes pureplay pharma/biopharma, sequencing instruments, gene editing, and assistive tech.
uBiome has filed 113 patents.
The 3 most popular patent topics include:
Molecular biology, DNA sequencing, Biotechnology, Bioinformatics, Genomics
Molecular biology, DNA sequencing, Biotechnology, Bioinformatics, Genomics
Latest uBiome News
Apr 11, 2023
News Provided By Share This Article Key Players in Gut Microbiome Test Market are Viome, Inc., uBiome Inc., Wellnicity, BIOHM, Psomagen” — Emergen Research VANCOUVER, BRITISH COLUMBIA, CANADA, April 11, 2023 / EINPresswire.com / -- The Latest research study released by Emergen Research on " Gut Microbiome Test Market " with 150+ pages of analysis on business Strategy taken up by key and emerging industry players and delivers know how of the current market development, landscape, technologies, drivers, opportunities, market viewpoint and status. Understanding the segments helps in identifying the importance of different factors that leads the market growth. An extensive network of microbiomes is present in a human body, which comprises all the genetic material included in a microbiota, such as in the human gut or oral cavity. Microbiome tests are primarily used to screen for the presence of different microorganisms in the human feces. The test results provide extensive information about the microbiome’s richness in the gut, the microbiome’s diversity, and its comparison with other results. The test requires a sample of feces to be collected in a collection container and then analyzed in the laboratory. Through the test, the microbiome study is carried out to determine their involvement and role in human health and diseases, as some of the microbiomes are pathogenic, while some are beneficial. To Get Free Sample PDF Copy of This Report COVID-19 Impact Analysis The post-COVID-19 phase has undergone substantial change, and Gut Microbiome Test Market research highlights the opportunities and difficulties that still exist. This study report thoroughly examines the effects of the COVID-19 pandemic on the global economy and post-pandemic market behaviour. Gut Microbiome Test Market: Dynamics The rapid advancement in the diagnostic testing and sequence-based analysis of the microbiome is expected to enhance the industry’s growth. The gut microbiome tests have the capability of detecting specific gut infections and diseases such as irritable bowel syndrome (IBS) and inflammatory bowel disease (IBD). Microbiome testing, also known as gut flora testing, has witnessed a surge in demand and advancements over the last couple of years. With the advent of testing kits that can be deployed in home-settings, the market has seen substantial growth as testing at home for the gut microbiome has become relatively more comfortable. These tests are beneficial for people who are curious about their bodies and want to delve deeper into their gastrointestinal tract health. The rising awareness of the microbiota’s role in the development of disease and pathogenesis, coupled with the exploitation of microbiome-based therapies, has bolstered the growth of the gut microbiome testing in the medical field. The researchers and healthcare companies are actively engaged in discovering novel therapeutic strategies that include the gut microbiome. The market growth is primarily attributed to the increasing development of microbiome therapy, drug development, and the rapid availability of the gut microbiome testing kits. Additionally, the rise in home care services and seamless reimbursement policies are expected to add traction to the market’s growth. However, less awareness among people, less accuracy, and data security concerns, coupled with extensive pipeline products and stringent FDA regulations, are expected to hinder the growth of the market. Ask for Customization Regional Outlook We carefully examined each division, regional classification, national study, and subject-specific data set during the market research. This Gut Microbiome Test Market research report's goal is to look at growth patterns, promising futures, important obstacles, and expected results. Information on significant market participants, strategic alliances, plans, new product launches, and joint ventures are all included in the research. Key Reasons to Purchase Gut Microbiome Test Market Report The reader will be in a position to comprehend and react to marketing strategies like using strengths and conducting a SWOT analysis. The research looks into the dynamics of the target market and how the conflict between Russia and Ukraine has affected it. Look Over transcripts provided by Emergen Research Patient Temperature Monitoring Market About Us: Emergen Research is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target, and analyse consumer behavior shifts across demographics, across industries, and help clients make smarter business decisions. We offer market intelligence studies ensuring relevant and fact-based research across multiple industries, including Healthcare, Touch Points, Chemicals, Types, and Energy. We consistently update our research offerings to ensure our clients are aware of the latest trends existent in the market. Emergen Research has a strong base of experienced analysts from varied areas of expertise. Our industry experience and ability to develop a concrete solution to any research problems provides our clients with the ability to secure an edge over their respective competitors. Eric Lee
uBiome Frequently Asked Questions (FAQ)
When was uBiome founded?
uBiome was founded in 2012.
Where is uBiome's headquarters?
uBiome's headquarters is located at 180 Steuart Street, San Francisco.
What is uBiome's latest funding round?
uBiome's latest funding round is Asset Sale.
How much did uBiome raise?
uBiome raised a total of $109.87M.
Who are the investors of uBiome?
Investors of uBiome include Macrogen, 8VC, Y Combinator, OS Fund, Dentsu Ventures and 9 more.
Who are uBiome's competitors?
Competitors of uBiome include Viome and 2 more.
Compare uBiome to Competitors
DayTwo provides personalized nutrition and insights to maintain normal blood sugar levels. It uses microbiome data to change the outlook on chronic disease. The company empowers members with personalized tweaks to their nutrition plans that regulate blood sugar levels. It offers metrics and microbiomes to gain detailed information for personalized results. The company was founded in 2015 and is based in Walnut Creek, California.
Everly Health provides an e-commerce platform. It enables customers to buy a variety of test kits online, collect their samples at home, and get results without visiting a lab or doctor's office. It offers various at-home lab tests such as sexual health, thyroid, metabolism, men's health, and more. The company was formerly known as Everly Well. It was founded in 2015 and is based in Austin, Texas.
LifeNome provides genomics artificial intelligence (AI) based technology to improve the health and well-being of customers. It uses systems-biology, multi-omics, and proprietary artificial intelligence engines to personalize health and wellbeing services and products of healthcare, insurance, pharmaceutical, nutrition, and fitness organizations. The company was founded in 2016 and is based in New York, New York.
imaware operates as a healthcare service provider. It provides laboratory testing for wellness monitoring, informational, and educational use. It offers scientifically validated home-based tests to monitor men's health, women's health, allergic diseases, autoimmune diseases, preventative genetics, and more. It was founded in 2018 and is based in Houston, Texas.
Color operates as healthcare technology company. democratizes access to genetic information. It offers Color Test for patients to detect hereditary cancers such as breast, colorectal, melanoma, ovarian, pancreatic, prostate, stomach, and uterine cancers. It was formerly known as Color Genomics. It was founded in 2013 and is based in Burlingame, California.
Genoplan operates as a healthcare solution and biotechnology company. The company provides a modular business-to-business-to-customer platform that customizes health needs and offers genetic testing kits, technology, software solution, and more. It was founded in 2014 and is based in Seoul, South Korea.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.